Company Overview of rEVO Biologics, Inc.
rEVO Biologics, Inc., a biopharmaceutical company, develops and commercializes protein therapies for the treatment of rare and life-threatening conditions. The company offers ATryn, a recombinant human plasma-free antithrombin concentrate for hereditary deficiency. It is also developing PRESERVE-1 for the management of preeclampsia in weeks 24 to 28 of pregnancy. rEVO Biologics, Inc. sells its products to distributors in the United States, France, and rest of Europe. The company was formerly known as GTC Biotherapeutics, Inc. and changed its name to rEVO Biologics, Inc. in January 2013. The company was founded in 1993 and is headquartered in Framingham, Massachusetts. rEVO Biologics, Inc. is...
175 Crossing Boulevard
Framingham, MA 01702
Founded in 1993
Key Executives for rEVO Biologics, Inc.
Chief Executive Officer, President and Director
Chief Financial Officer, Principal Accounting Officer, Senior Vice President, Secretary and Treasurer
Vice President of Commercial Operations
Director of Contract Administration
Vice President of Clinical Development
Compensation as of Fiscal Year 2014.
rEVO Biologics, Inc. Key Developments
rEVO Biologics Seeks Acquisitions
Jun 25 14
rEVO Biologics, Inc. is looking for acquisitions. rEVO Biologics filed an initial public offering in the amount of $74.75 million. rEVO Biologics may use a portion of the net proceeds of this offering for the acquisition or licensing, as the case may be, of additional products or product candidates, other assets or businesses, or for other strategic investments or opportunities, although it has no current understandings, agreements or commitments to do so.
rEVO Biologics Announces the Submission of an IND for ATryn(R) in Preeclampsia
Feb 25 14
rEVO Biologics announced the submission of an Investigational New Drug (IND) Application with the US Food and Drug Administration (FDA) for ATryn(R) [antithrombin (Recombinant)] for the treatment of preeclampsia in pregnant women. The objective of the Phase 3 study (PRESERVE-1) is to assess whether ATryn(R) may safely prolong pregnancy in mothers with very early preterm preeclampsia and consequently decrease prematurity-associated morbidity and mortality of their babies. This study will focus on pregnant women who are at gestational age 24 to 28 weeks -- an area of significant unmet need. Babies born at these gestational ages have a high risk of mortality or severe morbidity. During this period, prolongation of pregnancy, even by a few days, can lead to a significant improvement in the well-being of the newborns. rEVO is seeking to expand the approved labeling for ATryn to include preeclampsia. ATryn is currently indicated for the prevention of peri-operative and peripartum thromboembolic events in hereditary antithrombin deficient patients. It is not indicated for the treatment of thromboembolic events. Preeclampsia is a life-threatening condition that occurs in approximately 6% to 8% of all pregnancies. In the United States (US), more than 200,000 pregnancies are affected by preeclampsia each year. Preeclampsia can occur any time after the twentieth week of pregnancy. It is particularly devastating when it occurs early during the pregnancy as it leads to the birth of severely premature babies. Very early preterm preeclampsia is a severe form of preeclampsia that arises before 28 weeks of gestation. It is estimated that between 0.15 and 0.2% of pregnancies in Western countries will be complicated by very early preterm preeclampsia, or 6,000 to 8,000 pregnancies in the US each year. If proven to be safe and effective, ATryn may be the first drug specifically indicated for the management of preterm preeclampsia in pregnant women.
rEVO Biologics Announces Completion of Dose Ranging Study of Novel, Recombinant Form of Factor VIIa in Patients with Hemophilia A and B
Jun 10 13
rEVO Biologics announced that it has completed the treatment and follow up phase of a key dose ranging study of LR769, a novel recombinant form of human Factor VIIa (rhFVIIa), in patients with congenital hemophilia A or B. Results from the study will be presented at the XXIV Congress of the International Society on Thrombosis and Haemostasis, which takes place June 29--July 4, 2013, in Amsterdam, The Netherlands. LR769 is a novel compound, developed in cooperation with LFB Biotechnologies and produced through proprietary rPRO transgenic technology. It is being developed for treatment of hemophilia A and B patients with inhibitors to Factor VIII or IX. This multicenter study was designed to assess the safety, pharmacokinetic and pharmacodynamic properties of LR769 at three dose levels. Each patient received two doses of LR769. The study was sponsored by rEVO and conducted at sites in the United States and in Europe. The pharmacokinetic and pharmacodynamic data will provide the basis for further clinical efficacy studies of LR769. rEVO will be working with global regulatory authorities, including FDA, to initiate a Phase 3 registrational study later this year.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|